North China Pharmaceutical Co Ltd

North China Pharmaceutical Co Ltd has a market capitalization of CNY 7.82 billion and a price-to-earnings ratio of 42.74, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio is 1.42, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 53.90, which is significantly higher than typical industry benchmarks, indicating a high valuation relative to its operating performance. The company's profitability metrics show a return on equity of 3.32% and a return on assets of 0.86%, both of which are below the industry median for pharmaceutical firms. The net income of CNY 183.06 million is modest compared to the company's total assets of CNY 21.39 billion, indicating limited profitability relative to its asset base. The gross profit margin is 31.2%, which is in line with the industry average, but the operating margin of 3.83% is below the median for the sector. The company's revenue is concentrated in a single geographic market, with the majority of its sales coming from China. There is no disclosed information on revenue by business segment, but the company's operations are primarily focused on pharmaceuticals. This concentration increases exposure to domestic economic and regulatory risks. The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The capital expenditure of CNY -542.01 million indicates a reduction in investment in new projects or facilities, which may signal a conservative approach to growth. The company's liquidity position is rated as medium, with a current ratio of 0.66, indicating that it has more current liabilities than current assets. The company faces several risk factors, including a high debt-to-equity ratio of 2.04, which suggests a significant reliance on debt financing. The risk assessment indicates a low potential for dilution, but the company's net cash position is negative after accounting for total debt, which could limit its financial flexibility. There are no recent significant events or filings that would indicate a material change in the company's risk profile. The company's ESG profile is mixed, with a social pillar score of 29.31 and a governance pillar score of 26.21, both of which are below the industry median. The ESG controversies score is 100.00, indicating that the company has not been involved in any recent ESG-related controversies.